Cuba’s Quimi-Vio Vaccine: A Breakthrough in Combating Pneumococcal Diseases
In a significant stride for public health, Cuba’s Quimi-Vio vaccine has entered clinical trials, offering hope for millions battling pneumococcal diseases. Designed to combat conditions like pneumonia, meningitis, and sepsis caused by Streptococcus pneumoniae, this vaccine marks a pivotal moment in medical innovation.
the vaccine, developed by the Finlay Vaccine Institute (IFV), is administered as a single intramuscular dose in the deltoid muscle. Common side effects are mild and localized, including pain, redness, and swelling at the injection site. Some recipients may also experience general symptoms like weakness, fever, or headache, typical of most vaccines.
dr. Meiby de la Caridad Rodríguez, a leading researcher, emphasized the urgency of this development. In Cuba, even though the greatest epidemiological burden of pneumococcal disease is concentrated in the child population under five years of age, in the adult population there is also a high morbidity and mortality,
she stated.With nearly 24.4% of Cuba’s population aged 60 or older as of 2023, the vaccine is particularly critical for an aging demographic vulnerable to chronic illnesses.
Pneumococcal diseases rank as the fourth leading cause of death in cuba,with the majority of fatalities occurring in adults over 60. Dr. Rodríguez highlighted the heightened risks: People aged 65 and over have a 3.8 times greater risk of suffering from pneumococcus pneumonia, compared to healthy adults aged 18 to 64.
For those with chronic conditions like diabetes or cardiovascular disease, the risk increases by 2.8 and 3.8 times, respectively.
The vaccine’s journey to development spans over a decade. After rigorous clinical trials, Quimi-Vio received health registration from Cecmed in July 2024 for use in children aged one to five. As september 2024, over 95,000 infants have been vaccinated nationwide, showcasing its safety and efficacy.
Produced at the National Center for Biopreparations (Biocen), Quimi-Vio is a testament to Cuba’s scientific prowess.Its potential to safeguard both children and adults underscores a commitment to healthier aging and disease prevention. As the vaccine moves closer to widespread availability, it represents a beacon of hope for a healthier future.
